Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments
Abstract It has not been elucidated whether incretins affect insulin clearance in type 2 diabetes (T2D). We aimed exploring possible associations between insulin clearance and endogenously secreted or exogenously administered incretins in T2D patients. Twenty T2D patients were studied (16 males/4 fe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-06402-5 |
| _version_ | 1828865524866482176 |
|---|---|
| author | Andrea Tura Christian Göbl Irfan Vardarli Giovanni Pacini Michael Nauck |
| author_facet | Andrea Tura Christian Göbl Irfan Vardarli Giovanni Pacini Michael Nauck |
| author_sort | Andrea Tura |
| collection | DOAJ |
| description | Abstract It has not been elucidated whether incretins affect insulin clearance in type 2 diabetes (T2D). We aimed exploring possible associations between insulin clearance and endogenously secreted or exogenously administered incretins in T2D patients. Twenty T2D patients were studied (16 males/4 females, 59 ± 2 years (mean ± standard error), BMI = 31 ± 1 kg/m2, HbA1c = 7.0 ± 0.1%). Patients were treated with metformin, sitagliptin, metformin/sitagliptin combination, and placebo (randomized order). On each treatment period, oral and isoglycemic intravenous glucose infusion tests were performed (OGTT, IIGI, respectively). We also studied twelve T2D patients (9 males/3 females, 61 ± 3 years, BMI = 30 ± 1 kg/m2, HbA1c = 7.3 ± 0.4%) that underwent infusion of GLP-1(7–36)-amide, GIP, GLP-1/GIP combination, and placebo. Plasma glucose, insulin, C-peptide, and incretins were measured. Insulin clearance was assessed as insulin secretion to insulin concentration ratio. In the first study, we found OGTT/IIGI insulin clearance ratio weakly inversely related to OGTT/IIGI total GIP and intact GLP-1 (R2 = 0.13, p < 0.02). However, insulin clearance showed some differences between sitagliptin and metformin treatment (p < 0.02). In the second study we found no difference in insulin clearance following GLP-1 and/or GIP infusion (p > 0.5). Thus, our data suggest that in T2D there are no relevant incretin effects on insulin clearance. Conversely, different antidiabetic treatments may determine insulin clearance variations. |
| first_indexed | 2024-12-13T04:30:49Z |
| format | Article |
| id | doaj.art-a0ab9c0d6a504560aaa3669a917fa54a |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-13T04:30:49Z |
| publishDate | 2022-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-a0ab9c0d6a504560aaa3669a917fa54a2022-12-21T23:59:33ZengNature PortfolioScientific Reports2045-23222022-02-0112111010.1038/s41598-022-06402-5Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatmentsAndrea Tura0Christian Göbl1Irfan Vardarli2Giovanni Pacini3Michael Nauck4CNR Institute of NeuroscienceDepartment of Obstetrics and Gynaecology, Medical University of ViennaDiabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital (Ruhr University Bochum)Independent ResearcherDiabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital (Ruhr University Bochum)Abstract It has not been elucidated whether incretins affect insulin clearance in type 2 diabetes (T2D). We aimed exploring possible associations between insulin clearance and endogenously secreted or exogenously administered incretins in T2D patients. Twenty T2D patients were studied (16 males/4 females, 59 ± 2 years (mean ± standard error), BMI = 31 ± 1 kg/m2, HbA1c = 7.0 ± 0.1%). Patients were treated with metformin, sitagliptin, metformin/sitagliptin combination, and placebo (randomized order). On each treatment period, oral and isoglycemic intravenous glucose infusion tests were performed (OGTT, IIGI, respectively). We also studied twelve T2D patients (9 males/3 females, 61 ± 3 years, BMI = 30 ± 1 kg/m2, HbA1c = 7.3 ± 0.4%) that underwent infusion of GLP-1(7–36)-amide, GIP, GLP-1/GIP combination, and placebo. Plasma glucose, insulin, C-peptide, and incretins were measured. Insulin clearance was assessed as insulin secretion to insulin concentration ratio. In the first study, we found OGTT/IIGI insulin clearance ratio weakly inversely related to OGTT/IIGI total GIP and intact GLP-1 (R2 = 0.13, p < 0.02). However, insulin clearance showed some differences between sitagliptin and metformin treatment (p < 0.02). In the second study we found no difference in insulin clearance following GLP-1 and/or GIP infusion (p > 0.5). Thus, our data suggest that in T2D there are no relevant incretin effects on insulin clearance. Conversely, different antidiabetic treatments may determine insulin clearance variations.https://doi.org/10.1038/s41598-022-06402-5 |
| spellingShingle | Andrea Tura Christian Göbl Irfan Vardarli Giovanni Pacini Michael Nauck Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments Scientific Reports |
| title | Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments |
| title_full | Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments |
| title_fullStr | Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments |
| title_full_unstemmed | Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments |
| title_short | Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments |
| title_sort | insulin clearance and incretin hormones following oral and isoglycemic intravenous glucose in type 2 diabetes patients under different antidiabetic treatments |
| url | https://doi.org/10.1038/s41598-022-06402-5 |
| work_keys_str_mv | AT andreatura insulinclearanceandincretinhormonesfollowingoralandisoglycemicintravenousglucoseintype2diabetespatientsunderdifferentantidiabetictreatments AT christiangobl insulinclearanceandincretinhormonesfollowingoralandisoglycemicintravenousglucoseintype2diabetespatientsunderdifferentantidiabetictreatments AT irfanvardarli insulinclearanceandincretinhormonesfollowingoralandisoglycemicintravenousglucoseintype2diabetespatientsunderdifferentantidiabetictreatments AT giovannipacini insulinclearanceandincretinhormonesfollowingoralandisoglycemicintravenousglucoseintype2diabetespatientsunderdifferentantidiabetictreatments AT michaelnauck insulinclearanceandincretinhormonesfollowingoralandisoglycemicintravenousglucoseintype2diabetespatientsunderdifferentantidiabetictreatments |